Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

1. Pharmacokinetic interactions with thiazolidinediones.Clinical pharmacokinetics · 2007
   Review
2. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.Drug safety · 2005
   Review
3. Hepatotoxicity with thiazolidinediones: is it a class effect?Drug safety · 2001
   Review
4. Inferences from targeting CYP450 modulation to decrease the risk of induced cataract in the experimental model?Indian journal of ophthalmology
   Article

Corrections and comments

• Comment on
  Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.2000

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as